Inhibition of Ubiquitin Phosphorylation by Nucleoside Analogues

22 December 2022, Version 1

Abstract

The phosphorylation of ubiquitin by the mitochondrial protein kinase PINK1, upon mitochondrial depolarization, is an important step in the repair and recycling of the mitochondria via mitophagy. As mutations in PINK1 can cause early-onset Parkinson’s disease (PD), there has been a growing interest in small molecule modulators of PINK1-mediated mitophagy as potential PD treatments. In this work, we show that in HeLa cells, primary mouse fibroblasts and astrocytes, N6-substituted adenosines, such as N6-(2- furanylmethyl)adenosine (known as kinetin riboside) and N6-benzyladenosine, inhibit ubiquitin phosphorylation that is induced by established mitochondrial depolarizing agents, CCCP and niclosamide. Although these nucleoside analogues inhibited niclosamide- and CCCP-induced ubiquitin phosphorylation, they did not prevent the mitochondrial membrane depolarization. Notably, treatment of cells with these nucleoside analogues alone induced low level mitophagy and did not cause mitochondrial fragmentation. Together, this work presents N6-substituted adenosines as new inhibitors of CCCP- and niclosamide-induced PINK1-mediated ubiquitin phosphorylation and highlights their potential utility in treating aged and sporadic PD as well as Lewy body dementia patients who have elevated levels of phosphorylated ubiquitin.

Keywords

Ubiquitin
Phosphorylation
PINK1
Mirophagy
Nucleoside
Parkinson's disease
Dementia
Mitochondria

Supplementary materials

Title
Description
Actions
Title
Supporting Information for "Inhibition of Ubiquitin Phosphorylation by Nucleoside Analogues".
Description
Supporting Figures S1-S10, experimental methods and compounds characterisation.
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.